The short version of c-Met receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-05. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
== History == Both Adolf Jarisch, an Austrian dermatologist, and Karl Herxheimer, a German dermatologist, are credited with the discovery of the Jarisch–Herxheimer reaction. Both Jarisch and Herxheimer observed reactions in patients with syphilis treated with mercury. The reaction was first seen following treatment in early and later stages of syphilis treated with Salvarsan, mercury, or antibiotics. Jarisch thought that the reaction was caused by a toxin released from the dying spirochetes.
The Lutheran church was the state church of the Kingdom of Hanover, with the King being summus episcopus (Supreme Governor of the Lutheran Church). Regional consistories supervised church and clergy. These were in Aurich, a simultaneously Lutheran and Calvinist consistory dominated by Lutherans (for East Frisia) and the Lutheran consistories in Hanover (for the former Electorate of Brunswick-Lüneburg proper), in Ilfeld (for the County of Hohenstein, a Hanoverian exclave in the Eastern Harz mountains), in Osnabrück (for the former Prince-Bishopric of Osnabrück), in Otterndorf (existed 1535–1885 for the Land of Hadeln) as well as in Stade (existed 1650–1903, until 1885 for the former Bremen-Verden proper without Hadeln, then including the complete Stade region). A general superintendent chaired each consistory. In 1848, the Lutheran parishes were democratised by the introduction of presbyteries (German: Kirchenvorstände, singular Kirchenvorstand; literally: church boards), elected by all major male parishioners and chairing each congregation in co-operation with the pastor, being before the sole chairman. This introduction of presbyteries was somewhat revolutionary in the rather hierarchically structured Lutheran church. In 1864, Carl Lichtenberg, Hanoverian minister of education, cultural and religious affairs (1862–65), persuaded the Ständeversammlung (lit. Estates Assembly, the Hanoverian parliament) to pass a new law as to the constitution of the Lutheran church. The constitution provided a state synod (parishioners' parliament, German: Landessynode).
Nitrilotriacetic acid (NTA) is the aminopolycarboxylic acid with the formula N(CH2CO2H)3. It is a colourless solid. Its conjugate base nitrilotriacetate is used as a chelating agent for Ca2+, Co2+, Cu2+, and Fe3+.
The majority of human neoantigens identified in unbiased screens display a high predicted MHC binding affinity. Minor histocompatibility antigens, a conceptually similar antigen class are also correctly identified by MHC binding algorithms. Another potential filter examines whether the mutation is expected to improve MHC binding. The nature of the central T-cell receptor-exposed residues of MHC-bound peptides is associated with peptide immunogenicity.
Sources: en.wikipedia.org
=== Size and other body parts === There is no correlation between shoe size and stretched penis size. Nose size was highly related to stretched penile length in Japanese male cadavers. There may be a link between the malformation of the genitalia and the human limbs. The development of the penis in an embryo is controlled by some of the same Hox genes (in particular HOXA13 and HOXD13) as those that control the development of the limbs. Mutations of some Hox genes that control the growth of limbs cause malformed genitalia (hand–foot–genital syndrome).
=== Asthma === Patients' response to inhaled corticosteroids has some basis in genetic variations. Two genes of interest are CHRH1 (corticotropin-releasing hormone receptor 1) and TBX21 (transcription factor T-bet). Both genes display some degree of polymorphic variation in humans, which may explain how some patients respond better to inhaled corticosteroid therapy than others. However, not all asthma patients respond to corticosteroids and large sub groups of asthma patients are corticosteroid resistant. A study funded by the Patient-Centered Outcomes Research Institute of children and teens with mild persistent asthma found that using the control inhaler as needed worked the same as daily use in improving asthma control, number of asthma flares, how well the lungs work, and quality of life. Children and teens using the inhaler as needed used about one-fourth the amount of corticosteroid medicine as children and teens using it daily.
Papillomas and warts/verrucae: They are caused by various strains of the human papilloma virus (HPV) of which there are more than 100 strains but usually due to HPV types 6 and 11. Papillomas are mostly spiky, finger like projections, or cauliflower head rounded lobular shaped. Usually painless and singular. Verrucae usually appear on the lips. Verrucae vulgaris is associated with HPV types 2 and 4. HPV types 16 and 18, designated high risk due to association with cancers, do not present like this in the oral mucosa but as white patches. Multifocal epithelial hyperplasia (Heck disease) is rare, usually familial, swellings appear in multiples and are more common to some Native American and Inuit groups. Verruciform xanthoma, a rare lesion which may resemble papilloma, is often white due to hyperkeratosis, usually appear in 50-70 year age group, commonly on the gingivae. They may be mistaken for papilloma or verrucous leukoplakia but are benign.
Rates of MI for a given age have decreased globally between 1990 and 2010. In 2011, an MI was one of the top five most expensive conditions during inpatient hospitalizations in the US, with a cost of about $11.5 billion for 612,000 hospital stays.
PD-L1, an immunosuppressive PD-1 ligand, is highly expressed in several cancers; the role of PD-1 in cancer immune evasion is well established. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer. Inhibition of the interaction between PD-1 and PD-L1 can enhance T-cell responses in vitro and mediate preclinical antitumor activity. This is known as immune checkpoint blockade. PD-1 is expressed intrinsically in some tumor cells, such as melanoma, where it promotes tumor growth independently of the immune system. Inhibition of tumor cell-intrinsic PD-1 suppresses tumor growth, whereas overexpression or engagement by PD-L1 enhances tumorigenicity. Combination therapy using both anti-PD1 along with anti-CTLA4 therapeutics have emerged as important tumor treatments within the field of checkpoint inhibition. The effects of the two antibodies has been shown to be more effective than either antibody alone and does not appear to be redundant. Anti-CTLA4 treatment leads to an enhanced antigen specific T cell dependent immune reaction while anti-PD-1 appears to reactivate CD8+ T cells ability to lyse cancer cells. In clinical trials, combination therapy has been shown to be effective in reducing tumor size in patients that are unresponsive to single co-inhibitory blockade, despite increasing levels of toxicity due to anti-CTLA4 treatment. A combination of PD1 and CTLA4 induced up to a ten-fold higher number of CD8+ T cells that are actively infiltrating the tumor tissue.
Sources: en.wikipedia.org
In addition, medicine can be administered through the skin, by ointments or by means of adhesive patch, such as the nicotine patch or iontophoresis. The skin is an important site of transport in many other organisms. Water resistance: The skin acts as a water-resistant barrier so essential nutrients are not washed out of the body.
=== Monofunctional C1-tetrahydrofolate synthase === This enzyme is encoded by MTHFD1L and reversibly interconverts ADP + phosphate + 10-formyltetrahydrofolate to ATP + formate + tetrahydrofolate (EC 6.3.4.3).
Helium (from Ancient Greek: ἥλιος, romanized: helios, lit. 'sun') is a chemical element; it has symbol He and atomic number 2. It is a colorless, odorless, non-toxic, inert, monatomic gas and the first in the noble gas group in the periodic table. Its boiling point is the lowest among all the elements, and it does not have a melting point at standard pressures. It is the second-lightest and second-most abundant element in the observable universe, after hydrogen. It is present at about 24% of the total elemental mass, which is more than 12 times the mass of all the heavier elements combined. Its abundance is similar to this in both the Sun and Jupiter, because of the very high nuclear binding energy (per nucleon) of helium-4 with respect to the next three elements after helium. This helium-4 binding energy also accounts for why it is a product of both nuclear fusion and radioactive decay. The most common isotope of helium in the universe is helium-4, the vast majority of which was formed during the Big Bang. Large amounts of new helium are created by nuclear fusion of hydrogen in stars. Helium was first detected as an unknown, yellow spectral line signature in sunlight during a solar eclipse in 1868 by Georges Rayet, Captain C. T. Haig, Norman R. Pogson, and Lieutenant John Herschel, and was subsequently confirmed by French astronomer Jules Janssen. Janssen is often jointly credited with detecting the element, along with Norman Lockyer. Janssen recorded the helium spectral line during the solar eclipse of 1868, while Lockyer observed it from Britain.
=== Primary lymphoid organs === The primary (or central) lymphoid organs, including the thymus, bone marrow, fetal liver, and yolk sac, are responsible for generating lymphocytes from immature progenitor cells in the absence of antigens. The thymus and the bone marrow constitute the primary lymphoid organs involved in the production and early clonal selection of lymphocyte tissues. Bird species' primary lymphoid organs include the bone marrow, thymus, bursa of Fabricius, and yolk sac.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.